Using Multimodal Biomarkers to Differentially Diagnose ADRDs for Clinical Trials (U19 Clinical Trial Optional)

Archived

National Institutes of Health

Description

The purpose of this funding opportunity is to enable multi-site clinical validation of a multimodal set of neuroimaging and biospecimen biomarkers to differentially diagnosis three or more similarly presenting neurodegenerative diseases, including at least one of the Alzheimers Disease and Related Dementias (ADRDs). As part of the program deliverables, investigators will be required to work towards qualifying the candidate biomarkers as therapeutic/drug development tools through the FDAs Biomarker Qualification Program. *Note this FOA has changed Council. ICs that previously joined are already in Shared Interest.

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public and State controlled institutions of higher education
  • Native American tribal governments (Federally recognized)
  • Public housing authorities / Indian housing authorities
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Private institutions of higher education
  • For-profit organizations other than small businesses
  • Small businesses
  • Others

Contact

NIH Grants Information<br/>grantsinfo@nih.gov
grantsinfo@nih.gov

Key dates & funding
  • PostedFeb 9, 2023
  • ClosesJun 1, 2023
  • Award ceiling$4,700,000
  • CFDA93.853, 93.866
Categories

Pro insight

Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.

Unlock with Pro